



Pleural Malignancy – A Rare Presentation

Dr. Suvarna Kalli Department Of Respiratory Medicine Dr. D.Y. Patil Medical College & Research Centre , Pune





- A 50 year old male , civil engineer , non smoker , K/C/ O DM-2 and CAD presented with complaints of
- Breathlessness
 Dry cough
 Right sided chest pain
- ➢ H/O Loss of weight
- History of fever during 1st week of illness.
- No H/O Wheeze / PND/ Orthopnea / Loss of appetite



CLINICAL EXAMINATION



- Conscious , Oriented
- No pallor/Icterus/clubbing/cyanosis/lymphadenopathy/ pedal edema

VITALS :

Afebrile Pulse rate – 94/min BP - 120/90 mmHg RR - 24/min SPO2 - 95% on Room air





- **R/S** Findings s/o Rt pleural effusion
- CVS S1 S2 present , no murmurs
- P/A Soft , no organomegaly
- CNS NAD



INVESTIGATIONS



НВ	11.5	Total Bilirubin	0.45	HBA1c	11.2
TLC	9200	Conjugated	0.16	Sr. Na	137
PBS	Normocytic Normochromic	Unconjugated	0.20	K+	4.1
Sr. urea	18	SGOT	20	CL	103
Creatinine	0.80	SGPT	21	Sr. uric acid	7.0
Sr.protien	8 gm%	Serum glucose	140 mg/dl		





CHEST X-RAY –

s/o Rt sided significant pleural effusion with contralateral mediastinal shift

USG THORAX -

Massive pleural effusion with septations







CECT THORAX



Gross Rt sided pleural effusion with atelectasis of Rt lung with thick enhancing pleura.





Thoracocentesis was performed , approximately 800 ml of turbid straw coloured fluid was aspirated.

Appearance	Turbid yellow	TLC	3000 /cmm	LDH	2440 U/L
Cob web	Not seen	DLC	N40,L20,M40	ADA	47 U/L
		Glucose	6mg/dl	ZN/GS C&S	
Malignant Cytology	Negative For Atypical	Protien	6 gm%	Leischman stain	Markedly cellular Predominately
(3 consecutive samples)	cells.	Sr.protiens	8 gm%		Polymorphs & Macrophages
		Serum glucose	140 mg/dl		

s/o complicated parapneumonic effusion





- Intercostal chest tube thoracostomy was done
- Inj. Amoxicillin + Clavulanic acid 1.2gms thrice daily was started

POST ICD XRAY...







- Around 3600 ml of turbid fluid was drained in 6 days
- ICD tube was removed when the drain was <50 ml for 48hrs
- Pt was discharged on Tab.
 Amoxicillin + Clavulanic acid
 625mg thrice daily with the diagnosis

Complicated Parapneumonic Effusion (BTS criteria)

ON DISCHARGE..







7 DAYS LATER....

Patient presented back to us after one week with the same complaints .

- CHEST XRAY : s/o Rt sided pleural effusion
- <u>USG THORAX</u> : s/o Moderate
 <u>Right sided pleural effusion</u>
 with collapse of underlying
 lung parenchyma







Diagnostic thoracocentesis was performed.

Appearance	Turbid yellow	TLC	2200/cmm	ADA	42 U/L
Cob web	Not seen	DLC	N20,L10, M30, Polymorphic cells-40%	Proteins	5.87 gm%
Sr.Glucose	160mg /dl	Glucose	1mg/dl	ZN/GS/C&S	No micro organisms seen
Sr.proteins	8 gm%	LDH	1270 U/L	Malignant cytology	Negative

complicated parapneumonic effusion





<u>BRONCHOSCOPY</u> –

No obvious endobronchial mass / any abnormalities seen.







Intermediate Bronchus

Main Carina





THORACOSCOPY

- Patient presented with
 - -Recurrent complicated pleural effusion despite of being treated adequately
 - -CT thorax s/o pleural thickening

Thoracoscopy was done for getting a tissue diagnosis.

Revealed numerous small pleural nodules covering entire parietal & visceral pleural surfaces.









HISTOPATHOLOGICAL EXAMINATION





H&E STAIN 400





The sampled tissue was **<u>Positive for Malignancy</u>**

Based on the investigations done the differentials were-

A)Malignant mesothelioma B)Adenocarcinoma

For confirmation IHC was done.



IMMUNO HISTOCHEMISTRY





IHC Marker Calretinin (400x)



IHC Marker EMA (400x)











PET SCAN :

- Right sided loculated pleural effusion with FDG avid pleural thickening.
- Few weakly metabolic mediastinal nodes.
- No FDG avid distant metastasis







DIAGNOSIS

Malignant pleural mesothelioma

(T1 N2 M0)



Follow up



Patient started on chemotherapy (Pemetrexed + Carboplatin).

Total 10 cycles of chemotherapy have been prescribed , currently 8 cycles of chemotherapy was done.





Review chest x-ray after 8 cycles of chemotherapy showed Rt pleural effusion but pt was asymptomatic

<u>PLAN</u>

If patient develops symptomatic pleural effusion



After 8 chemotherapy cycles...









 Malignant mesothelioma is a rare and insidious neoplasm with a poor prognosis.

peritoneal cavities ,tunica vaginalis & pericardium.

- Most cases of Malignant pleural mesothelioma have been associated with exposure to asbestos. (80% 90%)
- Rare causes Therapeutic ionizing irradiation to supradiaphragmatic fields, intrapleural thorium dioxide ,inhalation of other fibrous silicates such as erionite , simian virus 40.





Journal of Surgical Oncology / Volume 49, Issue 3

Article

Primary pleural mesotheliomas in south India: A 25-year study

Usha Kini MD, DCP, DNBE, Shameem Shariff MD, Dr. John A. Thomas MD, DHE

First published:March 1992

Only 15 cases were reported (1992)

Lung India

Case Report

Malignant pleural mesothelioma

Sukhesh Rao

Department of Tuberculosis and Respiratory Diseases, Yenepoya Medical College, Mangalore-575 018, Karnataka, India

ABSTRACT

Malignant mesothelioma is one of the rare tumors of pleura. One such case in a 57-year-old male, who presented we hemorrhagic pleural effusion and had no history of asbestos exposure, is reported here. The rarity, unusual presentation and implications are discussed.

Only 3 cases were reported in this 10 year study

Year: 2018 | Volume: 55 | Issue: 2 | Page: 190-195

Malignant mesothelioma: A histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India

Monalisa Hui¹, Shantveer Gurulingappa Uppin¹, Kakarla Bhaskar², Narahari Narendra Kumar², Gongati Kruparao Paramjyothi²

¹ Department of Pathology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India

² Department of Respiratory Medicine, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India

24 cases (2018)





Most commonly presents in 5th-6th decades of life.

Most frequent presenting symptoms -

- Non pleuritic chest pain (60 70%)
- Dyspnea(25%)
- Cough(20%).

Typically unilateral disease only 10 % have B/L involvement

Prognosis is **Poor**, with overall survival being 9-17 months after diagnosis.







TNM staging

Primary Tumor (T) :

- **TX** Primary tumor cannot be assessed
- **TO** No evidence of primary tumor

T1 Tumor limited to the ipsilateral parietal pleura with or without involvement of Visceral pleura, Mediastinal pleura & Diaphragmatic pleura

- T2 Tumor involving each of the ipsilateral pleural surfaces with at least one of the following features: Involvement of diaphragmatic muscle , Extension of tumor from visceral pleura into the underlying pulmonary parenchyma
- **T3** Locally advanced but potentially resectable tumor.

Locally advanced technically unresectable tumor.





<u>Regional lymph nodes (N):</u>

- NX Regional lymph nodes cannot be assessed
- NO No regional lymph node metastases
- N1 Metastases in the ipsilateral lymphnodes
- N2 Metastases in the contralateral mediastinal, ipsilateral or contralateral supraclavicular lymph nodes

• Distant metastasis (M):

M0 - No distant metastasisM1 - Distant metastasis present



Prognostic stage groups









Chest x-ray

Diffuse pleural thickening on left side with ipsilateral volume loss

CECT

Circumferential pleural thickening with ipsilateral volume loss









Multimodality treatment programs includes :

- Surgical cytoreduction (Extra pleural pneumonectomy(EPP), Parietal pleurectomy, Complete parietal & visceral pleurectomy
- Chemotherapy Cisplatin + Pemetrexed
 Pemetrexed + Carboplatin
- Radiotherapy
- Immunotherapy
- Gene Therapy

Under trial





Acknowledgements :

Department of pathology





Thank you...